Syndax Pharmaceuticals (SNDX) Equity Ratio (2015 - 2026)

Syndax Pharmaceuticals' Equity Ratio history runs 12 years deep, the most recent figure standing at 0.09 for Q1 2026.

• In Q1 2026, Equity Ratio fell 73.77% year-over-year to 0.09; the TTM figure through Mar 2026 stood at 0.09 (down 73.77% YoY), while the FY2025 annual figure was 0.12, down 69.31% from the prior year.
• Equity Ratio was 0.09 for Q1 2026 at Syndax Pharmaceuticals, down from 0.12 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2023 to a low of 0.09 in Q1 2026.
• Historically, Equity Ratio has averaged 0.67 across 5 years, with a median of 0.89 in 2022.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio increased 13.13% in 2022, then slumped 75.69% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.94 in 2022, then retreated by 3.81% to 0.9 in 2023, then slumped by 56.04% to 0.4 in 2024, then sank by 69.31% to 0.12 in 2025, then decreased by 27.83% to 0.09 in 2026.
• The last three Equity Ratio figures came in at 0.09 (Q1 2026), 0.12 (Q4 2025), and 0.21 (Q3 2025), per Business Quant data.